Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. announced that data from the randomized phase III Alcanza clinical trial evaluating Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma was published in Lancet.
A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.
